AstraZeneca
-
Britain’s biggest drugmaker acquires Seattle-based firm Icosavax, expanding vaccine and immune therapy business
-
UK drugmaker signs agreement with China’s Eccogene to work on an obesity and type 2 diabetes pill
-
CEOs received average increase of 16% while pay of many working for them failed to keep up with inflation
-
The man who led the drive to create a not-for-profit Covid vaccine is now focusing on the deaths caused by global heating and pollution
-
Pascal Soriot says decline in startups across Europe differs markedly from ‘explosion’ of firms and clinical trials in China
-
Viewpoint columnClimate emergency is the biggest health crisis of our time – bigger than CovidPascal Soriot
-
Quitting the EU has stalled business investment, making us reliant on workers who are now scarce. Hence rising wages, high inflation and increased interest rates. Result? A looming recession
-
Nils Pratley on financeTake AstraZeneca’s warning seriously. The UK is missing out in life sciencesBig pharma has choices about where to make new investments and, increasingly it seems, it is not choosing Britain
-
Brexit fallout plus funding fears mean an uncertain prognosis, but the firm will report good news this week
-
Scientists ditch plans to develop nasal spray version of Oxford/AstraZeneca vaccine in its current form
-
JCVI says mRNA vaccines such as the Pfizer and Moderna jabs are the most effective for UK booster programme
-
Government pledged to donate millions of doses to other countries but they were ‘not accepted’ despite fresh rise in coronavirus cases around the world
-
Firm aims to apply ‘equity lens’ across clinical tests to ensure diverse population groups take part
-
Pharmaceutical CEO says it’s ‘sad’ that UK has failed to order Evusheld for the immunosuppressed
-
Mark Hartigan has been given £511,000 bonus for 2021 – a humbler CEO would have let the dust settle